You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF V600E mutation

Showing 1 - 25 of 6,352
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

Not yet recruiting
  • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
  • Non-investigational
  • (no location specified)
May 11, 2023

Cancer Trial (Dabrafenib, Trametinib)

Not yet recruiting
  • Cancer
  • (no location specified)
May 25, 2023

Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting
  • NSCLC
  • +4 more
  • Combind asprin with Trametinib and Dabrafenib
  • (no location specified)
Aug 4, 2023

Non Small Cell Lung Cancer Trial (HLX208+HLX10)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • HLX208+HLX10
  • (no location specified)
Nov 30, 2022

Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • BRAF V600E Mutation Positive
  • Encorafenib Oral Capsule + Cetuximab
  • (no location specified)
Jan 30, 2023

Metastatic Colorectal Cancer, mCRC Trial in Shenyang (HLX208)

Recruiting
  • Metastatic Colorectal Cancer
  • mCRC
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital
May 1, 2022

BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

Recruiting
  • Metastatic Non-small Cell Lung Cancer
  • BRAF V600 Mutation
    • Lyon, Rhône Alpes, France
      CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
    Sep 14, 2022

    Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH Trial in Beijing (HLX208)

    Recruiting
    • Langerhans Cell Histiocytosis
    • +3 more
    • Beijing, China
      Peking Union Medical College Hospital
    Dec 30, 2021

    CRC Trial in Shanghai (HLX208, Cetuximab Injection [Erbitux])

    Recruiting
    • CRC
    • HLX208
    • Cetuximab Injection [Erbitux]
    • Shanghai, China
      Fudan University Affiliated Oncology Hospital
    Dec 30, 2021

    Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago

    Recruiting
    • Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
    • +2 more
    • Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
    • Chicago, Illinois
      Northwestern University
    Nov 16, 2022

    BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

    Recruiting
    • BRAF NP_004324.2:p.V600M
    • +6 more
    • Portland, Oregon
      Providence Portland Medical Center
    Aug 17, 2022

    BRAF V600E Mutation Trial run by the NHGRI (Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide)

    Completed
    Has Results
    • BRAF V600E Mutation
    • Dabrafenib Mesylate
    • Trametinib Dimethyl Sulfoxide
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Aug 6, 2021

    Colorectal Cancer, Colon Cancer, BRAF V600E Trial (Binimetinib)

    Not yet recruiting
    • Colorectal Cancer
    • +4 more
    • (no location specified)
    Aug 18, 2022

    BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

    Active, not recruiting
    • BRAF V600E Mutation Present
    • +9 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2022

    NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +32 more
    • (no location specified)
    Mar 30, 2023

    NSCLC Trial in China (Dabrafenib, Trametinib)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Harbin, Heilongjiang, China
    • +9 more
    Jun 13, 2022

    Melanoma Trial in Beijing (HL-085, Vemurafenib)

    Recruiting
    • Melanoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 10, 2022

    BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

    Recruiting
    • BRAF NP_004324.2:p.V600E
    • +2 more
    • Duarte, California
    • +1 more
    Jan 19, 2023

    Anaplastic Thyroid Cancer, ATC Trial in Shanghai (HLX208)

    Recruiting
    • Anaplastic Thyroid Cancer
    • ATC
    • Shanghai, China
      Fudan University Affiliated Oncology Hospital
    Dec 30, 2021

    Brain Tumor, Primary Trial in Jinan (HLX208)

    Recruiting
    • Brain Tumor, Primary
    • Jinan, Shandong, China
      Cancer Hospital Affiliated to Shandong first medical University
    May 1, 2022

    BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

    Terminated
    • BRAF V600E Mutation Present
    • +7 more
    • Boston, Massachusetts
    • +1 more
    Mar 9, 2022

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

    Active, not recruiting
    • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 9, 2022

    Metastatic Colorectal Cancer, BRAF V600E Mutation Positive Trial in France (Collection of blood samples)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • BRAF V600E Mutation Positive
    • Collection of blood samples
    • Avignon, France
    • +26 more
    Nov 25, 2022

    Cancer, Cancer Metastatic, BRAF V600E Trial in Indianapolis (Abemaciclib, LY3214996)

    Recruiting
    • Cancer
    • +6 more
    • Indianapolis, Indiana
      Indiana University Hospital / IU Simon Cancer Center
    Jan 12, 2023

    First Line Treatment for BRAFV600E Mutant Metastatic Colorectal

    Completed
    • BRAF V600E Mutation Positive
    • Metastatic Colorectal Cancer
    • Non Interventional study
    • St. Veit/Glan, Austria
    • +33 more
    Jan 20, 2023